ResMed (RMD)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$228.35-0.37%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · RMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 8.5% |
| Our one-year growth estimate | diamond | 5.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers
RMD — legal / regulatory event — Changes in the Registrant’s Certifying Accountant
Dated 2026-08-17
Changes in the Registrant’s Certifying Accountant. (a) Dismissal of Previous Independent Registered Public Accounting Firm KPMG LLP (“KPMG”) was previously the principal accountants for ResMed Inc. (the “Company” or “Resmed”). On August 13, 2026, KPMG was dismissed, effective as of that date. The reports of KPMG on the Company’s consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualif…
Why it matters: The new CFO's plans can impact financial management and growth strategies. Investors will want to see how this affects ResMed's direction.
Watch forA press release will explain the new CFO's plans in three months.
Also watch forNo clear strategy or direction outlined by the new CFO within three months.
Why it matters: An increase shows confidence in cash flow and profits. It shows good capital management.
Supportive ifAnnouncement of a dividend increase above 10% in Q1 2027.
Worry ifNo dividend increase or a decrease in Q1 2027.
Why it matters: Aaron Bloomer's leadership may affect ResMed's financial strategy and execution. Investors will want to see if this change supports growth.
Watch forQ2 2026 earnings show continued revenue growth above 10% year over year.
Also watch forQ2 2026 earnings report shows revenue growth below 5% year over year.
Why it matters: Slower revenue growth may show market problems or more competition.
Worry ifRevenue growth stays above 10% in Q4 results.
Less concerning ifRevenue growth drops below 8% in Q4 results.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$143 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $302 loss on $10,000 · 3.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,515 loss on $10,000 · 35.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Strong revenue growth in digital health shows successful new ideas and market interest.
Supportive ifRevenue growth from digital health products exceeds 15% year over year in the next report.
Worry ifRevenue growth from digital health products is below 5% year over year in the next report.
Why it matters: A slowdown in sector growth could affect ResMed's performance. It signals broader market challenges.
Worry ifSector revenue growth drops below its median level.
Less concerning ifSector revenue growth is still higher than average. This shows strong performance.
Why it matters: Investing in innovation is crucial for growth. Increased spending signals confidence in future growth.
Supportive ifAnnouncement of new product launches or increased R&D spending.
Worry ifNo new product announcements or cuts to R&D budgets.
Why it matters: New products can drive growth and market share. Delays or failures could hurt future earnings.
Supportive ifThe new AI-powered medical device is popular. It sells very well.
Worry ifSales are low or feedback on the new product is bad. This shows market resistance.
Why it matters: The new CFO, Aaron Bloomer, may change financial strategies. This could affect growth and margins.
Watch forResMed shows better financial results under Aaron Bloomer's leadership. This includes higher gross margins and revenue growth.
Also watch forFinancial results drop or do not meet past goals. This shows a negative effect from the transition.
Why it matters: Investing in innovation is crucial for growth. Updates can show how ResMed is adapting to market needs.
Supportive ifAnnouncement of a new digital health product or service launch within six months.
Worry ifNo new product or service announcements in digital health within six months.
Why it matters: Good leadership changes help with strategy. Problems can happen if the change is not handled well.
Watch forThere are good updates about the CFO change and keeping the strategy on track.
Also watch forThere is bad feedback or issues with the CFO change.
Why it matters: Aaron Bloomer's leadership could change financial strategies and outcomes. Smooth transition is key.
Watch forGood financial results in the next two quarters after Aaron Bloomer becomes CFO.
Also watch forFinancial performance drops or stays the same after the CFO change.
Why it matters: Gross margin improvements are key to profitability. A drop could signal cost issues.
Worry ifGross margin remains above 62% in Q4 results.
Less concerning ifGross margin falls below 61% in Q4 results.
Why it matters: A higher dividend would show strong cash flow. It also shows a commitment to shareholders.
Supportive ifAnnouncement of a dividend increase above $0.60 per share in the next board meeting.
Worry ifNo increase in the dividend amount in the next board meeting.
Why it matters: Higher share repurchases indicate strong cash flow and confidence in the business. It can support stock price.
Supportive ifShare repurchases exceed $200 million in the next quarter.
Worry ifShare repurchases fall below $150 million in the next quarter.
Why it matters: Investments in digital health are crucial for future growth. Progress signals strong strategy.
Supportive ifNew digital health projects or partnerships may be announced in the next quarter.
Worry ifNo new digital health projects will be announced in the next quarter.
Why it matters: A drop in gross margin may show higher costs or problems in production.
Worry ifGross margin falls below 61% in Q1 2027.
Less concerning ifGross margin remains at or above 61% in Q1 2027.
Why it matters: This growth rate signals if demand for ResMed's products is slowing. A drop below 8% could indicate weakening market conditions.
Worry ifQ1 2027 revenue growth reported below 8% year over year.
Less concerning ifQ1 2027 revenue growth reported at or above 8% year over year.
Why it matters: Better margins show ResMed is handling costs well. Over 62% means strong efficiency.
Supportive ifGross margin reported above 62% in Q1 2027.
Worry ifGross margin reported below 61% in Q1 2027.
Why it matters: This sale could free up resources for innovation. Delays or issues may impact future growth plans.
Supportive ifCompletion of the MatrixCare business sale by the end of Q1 2027.
Worry ifDelays or problems in the MatrixCare sale process could be announced.
Why it matters: Smooth changes help keep things stable. Disruptions can damage trust and efficiency.
Watch forNo big changes in income or cash flow during the CFO change.
Also watch forBig drops in income or cash flow during the CFO change.